News Agency
Men's Weekly

HanAll Biopharma Signs Licensing Agreement with Turn Biotechnologies to Develop Novel Treatments for Eye and Ear Diseases

  • Written by PR Newswire
HanAll Biopharma Signs Licensing Agreement with Turn Biotechnologies to Develop Novel Treatments for Eye and Ear Diseases
  • Exclusive agreement allows HanAll to utilize Epigenetic Reprogramming of Aging (ERATM) technology for ophthalmic and otic diseases.
  • Collaboration aims to leverage HanAll's extensive expertise in ophthalmic and otic diseases and Turn Bio's cellular reprogramming technology to create innovative therapies.
  • Deal value can exceed $300 million USD for the...

Read more: HanAll Biopharma Signs Licensing Agreement with Turn Biotechnologies to Develop Novel Treatments...

Air Conditioner Sales Melbourne Helping You Choose The Right Cooling Solution

Creating a comfortable indoor environment often starts with choosing the right system, and that’s where air conditioner sales Melbourne become more than just a purchase decision. It’s about finding a solution that aligns with your space, lifestyle, and energy needs. With... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion